Prognostic Value of Cardiac and Renal Markers in Ischemic Stroke and Transient Ischemic Attack (ABC-AVC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00479518|
Recruitment Status : Completed
First Posted : May 28, 2007
Last Update Posted : February 27, 2017
|Condition or disease|
|Ischemic Stroke Transient Ischemic Attack|
Patients with ischemic stroke or TIA will be included in the 48 hours following the onset of symptoms, in 3 university hospitals.For each patient will be collected
- 1 blood sample for the BNP measure in pg/ml
- 1 blood sample for the Cystatin C measure in mg/l
- 2 urinary samples to measure the albumine/creatinine ratio, at inclusion and 5 days after the inclusion, and to study the variation of albuminuria in micrograms/min.
The clinical follow-up will be organized during 3 years. The following events will be notified: poor outcome (defined with the Barthel and Rankin scores), recurrence of cardiovascular or cerebrovascular events, vascular death.
After adjustment on the main clinical prognosis factors, we want to determine wich one of these markers has the best prognosis significance and allows to identify in the acute phase the "high-risk" patients, in order to intensify individual treatment and secondary prevention.
|Study Type :||Observational|
|Actual Enrollment :||159 participants|
|Official Title:||Prognostic Value of Cardiac and Renal Markers in the Acute Phase of Ischemic Stroke or Transient Ischemic Attack :Albuminuria-Brain Natriuretic Peptide-Cystatine C in Stroke|
|Actual Study Start Date :||March 2007|
|Actual Primary Completion Date :||April 2014|
|Actual Study Completion Date :||February 2017|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00479518
|Service de Neurologie / Hopital LAENNEC|
|Nantes, France, 44093|
|Service de neurologie / CHU Pontchaillou|
|Rennes, France, 35033|
|Service de Neurologie / CHRU de Tours|
|Tours, France, 37044|
|Principal Investigator:||BONNAUD Isabelle, MD||Service de Neurologie / CHRU de Tours|